Dr. Stagg is currently the director of the Goodman Cancer Institute at McGill University and a member of the management board at BioCanRx. They have held various prominent positions, including full professor at Université de Montréal and senior scientist at the Institut du cancer de Montréal. Dr. Stagg is recognized as a leader in immuno-oncology, having identified CD73 as a critical cancer target, which has influenced the development of therapeutic agents now in clinical trials. They co-founded Surface Oncology and played a key role in creating the Terry Fox Research Institute Marathon of Hope Cancer Centres Network. Dr. Stagg continues to contribute to scientific advisory boards for various biotechnology firms and is actively involved in advancing cancer precision medicine.
This person is not in the org chart
This person is not in any teams
This person is not in any offices